Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches

Clinical trial NCT02926638 · TERMINATED

Trial details

NCT number

NCT02926638

Sponsor

SWOG Cancer Research Network

Status

TERMINATED

Phase

Phase 2, Phase 3

Study type

INTERVENTIONAL

Start date

2014-06-16

Primary completion

2015-01-12

Enrollment

9

View on ClinicalTrials.gov